Monthly Tablets Help Women Persist Longer With Osteoporosis Drugs
Posted on: Friday, 21 July 2006, 12:00 CDT
Women who took an osteoporosis drug once a month and received extra telephone support from trained nurses showed 47% greater persistence with their drug treatment than those who took a weekly tablet, according to the results of a new study.
The Roche-supported study, named PERSIST, involved 103 primary care centers across the UK, with 1,076 women each agreeing to participate for a six-month period.
In the study, 542 women were prescribed a single 70mg dose of alendronate (marketed by Merck as Fosamax) once a week and the remainder received a single monthly 150mg dose of ibandronate (marketed as Boniva by Roche and GlaxoSmithKline) and were enrolled in a free patient support program designed to complement the drug.
The monthly ibandronate group received a welcome pack providing basic information about osteoporosis and a monthly reminder call from a trained nurse one to three days before the dose was due. The nurses also used the opportunity to confirm dosing instructions, provide further information about osteoporosis and stress the importance of adhering to the treatment regime.
835 women completed the study, leaving 440 in the monthly ibandronate group and 395 in the weekly alendronate group. Of these, just under 57% of patients receiving monthly ibandronate tablets, together with patient support, were taking the medication after six months. The persistence rate for patients on weekly alendronate tablets was 39%.
"Getting patients to continue taking prescribed medication is a major problem for healthcare professionals" says lead author Dr Alun Cooper, a family doctor from the Bridge Medical Centre in Crawley, UK. "Our study clearly shows that women who were prescribed monthly doses of ibandronate, and enrolled on a patient support program, were much more likely to continue taking their medication than those on weekly doses of alendronate."
Source: Datamonitor
Related Articles
- Study Evaluating Efficacy and Safety of Two Low-dose Regimens of PREMARIN Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published
- More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed Medications for OCD Receive Inadequate Therapy
- Covario Announces Results From Seven-Month Study of 300 Large Brand Web Sites
- Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison With Weekly Alendronate (FOSAMAX(R))
- Improving Medication Safety: Independent 18 Month Study of ValiMed(TM) Medication Validation System By CDEX Published in American Journal of Health-System Pharmacists
- Stark Study By GE Healthcare Predicts Accelerated Electronic Medical Record Adoption Within the Next Year
- Uncomplicated E Coli Urinary Tract Infection in College Women: A Follow-Up Study of E Coli Sensitivities to Commonly Prescribed Antibiotics
- LUNESTA(TM) Second Six-Month Study Results Presented at American Neurological Association Annual Meeting
- One in 4 Women Delay, Fail to Get Needed Medical Care
- LUNESTA(TM) Second Six-Month Study Data Confirms Findings of First Six-Month Study
 |
 |
User Comments (0)
RSS Feeds